Allakos Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Allakos de 21.5% y 84.1% respectivamente, mientras que el BPA crecerá en un 32.4% al año.

Información clave

21.5%

Tasa de crecimiento de los beneficios

32.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.4%
Tasa de crecimiento de los ingresos	84.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	26 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 04

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Oct 18

Allakos prices ~$150M underwritten offering

Sep 19

Allakos falls as lead asset offers mixed results in late-stage trial

Sep 09

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Aug 06

Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

Apr 22

Allakos: Sad End To A Promising Asset

Dec 23

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Dec 01

We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Aug 16

Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

Aug 06

Allakos provides lirentelimab clinical trial enrollment updates, names new CMO

Jun 07

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

May 02

Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?

Mar 10

Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling

Jan 28

We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow

Dec 07

Allakos EPS misses by $0.02

Nov 09

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ALLK - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-93	-100	N/A	4
12/31/2025	N/A	-76	-98	N/A	6
12/31/2024	N/A	-138	N/A	N/A	6
3/31/2024	N/A	-214	-119	-119	N/A
12/31/2023	N/A	-186	-117	-116	N/A
9/30/2023	N/A	-166	-140	-139	N/A
6/30/2023	N/A	-151	-139	-136	N/A
3/31/2023	N/A	-165	-142	-136	N/A
12/31/2022	N/A	-320	-288	-280	N/A
9/30/2022	N/A	-371	-322	-299	N/A
6/30/2022	N/A	-403	-350	-319	N/A
3/31/2022	N/A	-411	-371	-336	N/A
12/31/2021	N/A	-270	-241	-208	N/A
9/30/2021	N/A	-220	-195	-177	N/A
6/30/2021	N/A	-199	-174	-166	N/A
3/31/2021	N/A	-181	-143	-142	N/A
12/31/2020	N/A	-153	-115	-114	N/A
9/30/2020	N/A	-134	-99	-99	N/A
6/30/2020	N/A	-113	-79	-79	N/A
3/31/2020	N/A	-93	-69	-68	N/A
12/31/2019	N/A	-85	-64	-63	N/A
9/30/2019	N/A	-75	-60	-57	N/A
6/30/2019	N/A	-65	-55	-49	N/A
3/31/2019	N/A	-55	-49	-42	N/A
12/31/2018	N/A	-44	-45	-38	N/A
9/30/2018	N/A	-37	-38	-33	N/A
6/30/2018	N/A	-32	-32	-30	N/A
3/31/2018	N/A	-27	-27	-26	N/A
12/31/2017	N/A	-24	N/A	-23	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ALLK siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ALLK siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ALLK siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que ALLK no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que ALLK no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ALLK se prevé que sea elevada dentro de 3 años.

Allakos Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 32% to US$6.50

Price target decreased by 8.4% to US$9.08

Price target increased by 7.4% to US$8.67

Price target increased by 17% to US$8.50

Price target decreased by 19% to US$5.69

Price target increased to US$7.06

Recent updates

Allakos Inc. Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

Allakos Inc., Annual General Meeting, May 24, 2024

New minor risk - Market cap size

CEO & Director notifies of intention to sell stock

Allakos Inc. Announces Publication Highlighting AK006 Mast Cell Inhibition

New minor risk - Market cap size

Allakos Announces Restructuring to Focus on Development of AK006

New major risk - Share price stability

Price target decreased by 32% to US$6.50

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

Price target decreased by 8.4% to US$9.08

CEO & Director notifies of intention to sell stock

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

Price target increased by 7.4% to US$8.67

CEO & Director notifies of intention to sell stock

Allakos Inc. Appoints Neil Graham to its Board of Directors

Allakos Inc. Announces Board Appointments

Allakos Inc. Announces Board of Directors Appointment

Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth

CEO & Director notifies of intention to sell stock

Price target increased by 17% to US$8.50

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Chief Medical Officer notifies of intention to sell stock

Price target decreased by 19% to US$5.69

Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

CEO & Director notifies of intention to sell stock

Price target increased to US$7.06

Insufficient new directors

Price target increased to US$7.06

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Allakos prices ~$150M underwritten offering

Price target decreased to US$6.56

Allakos Inc. Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

Allakos falls as lead asset offers mixed results in late-stage trial

Price target decreased to US$7.11

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Allakos Inc. Announces the Appointment of Dr. Amy Ladd to Its Board of Directors

Allakos Inc.(NasdaqGS:ALLK) dropped from Russell 2000 Growth Index

Price target decreased to US$10.28

Insufficient new directors

Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

Allakos Inc. Announces Management Changes

Allakos Inc., Annual General Meeting, May 25, 2022

Allakos Inc. to Hold an End-Of-Phase 2 Meeting with the FDA During Second Quarter of 2022

Price target decreased to US$19.38

Allakos: Sad End To A Promising Asset

Price target decreased to US$51.44

Allakos Inc. Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

Allakos Inc. Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Independent Director exercised options and sold US$430k worth of stock

President & COO exercised options to buy US$6.2m worth of stock.

We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Allakos Provides Business Update

Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

Insufficient new directors

President & COO exercised options and sold US$3.6m worth of stock

CEO & Director exercised options and sold US$4.0m worth of stock

CEO & Director recently sold US$2.0m worth of stock

Allakos Inc. Completes Enrollment in Phase 3 Study of Lirentelimab in Patients with Eosinophilic Gastritis

Allakos provides lirentelimab clinical trial enrollment updates, names new CMO

Allakos Inc. Reports Data At Digestive Disease Week (DDW) 2021

Price target increased to US$149

President & COO exercised options and sold US$5.8m worth of stock

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Chief Medical Officer exercised options and sold US$5.6m worth of stock

Independent Director recently sold US$855k worth of stock